Identification of at-risk NASH patients
Flexible and affordable pay per exam offer.
All services included.
Screening of at-risk patients for early intervention.
Immediate medical decisions at the point-of-care for improved patient outcomes
and a higher healthcare efficiency.
Diagnosis, patient stratification, monitoring of disease progression.
A powerful tool for prognosis of disease course.
Integrates instantly into an office-based practice with small footprint and connectivity.
Enhanced clinical decision support with the Interpretation Guide and Scores by Echosens available on myFibroScan.
A smaller, mobile equipment for easy integration for multi-site configuration.
A centralized and secure data management with Echosens Cloud.
Online patient file for easier medical follow-up.
User management and exam activity monitoring.
FibroScan® is perfect for use in a primary care setting, it is portable and gives patients an instant result enabling them to leave with the result.
Fibroscan® is key to providing a Community service, which is part of the wider pathway to increase early detection and timely intervention and management of patients with and at-risk of liver disease.
FibroScan® as an interventional therapy helps primary care physicians and nurse specialists engage patients by demonstrating the results and outcomes as a value change.
Assists you with onsite installation and training.
Includes maintenance, calibration of probes and software updates.
Easy access to continuous training and users community with Echosens Academy.
FibroScan® 230 is a Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). This device is designed for use in a medical practice in order to provide liver stiffness measurement at 50 Hz shear wave frequency and liver ultrasonic attenuation (CAP) at 3.5 MHz ultrasound frequency. Liver stiffness and CAP are indicated as an aid to diagnosis and monitoring for adult and pediatric patients as part of an overall assessment of liver disease. Examinations with FibroScan® 230 device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies. FibroScan®, among others, are trademarks and/or service mark of Echosens Group.
1. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264.
2. Steadman R, et al. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol. 2013;27(3):149-158.